Literature DB >> 33630918

Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network.

Gonzague de Pinieux1, Marie Karanian2, Francois Le Loarer3, Sophie Le Guellec4, Sylvie Chabaud2, Philippe Terrier5, Corinne Bouvier6, Maxime Batistella7, Agnès Neuville3, Yves-Marie Robin8, Jean-Francois Emile9, Anne Moreau10, Frederique Larousserie11, Agnes Leroux12, Nathalie Stock13, Marick Lae13,14, Francoise Collin15, Nicolas Weinbreck16, Sebastien Aubert8, Florence Mishellany17, Celine Charon-Barra15, Sabrina Croce3, Laurent Doucet18, Isabelle Quintin-Rouet18, Marie-Christine Chateau19, Celine Bazille20, Isabelle Valo21, Bruno Chetaille16, Nicolas Ortonne22, Anne Brouchet4, Philippe Rochaix4, Anne Demuret1, Jean-Pierre Ghnassia23, Lenaig Mescam24, Nicolas Macagno6, Isabelle Birtwisle-Peyrottes25, Christophe Delfour19, Emilie Angot13, Isabelle Pommepuy26, Dominique Ranchere2, Claire Chemin-Airiau2, Myriam Jean-Denis2, Yohan Fayet2, Jean-Baptiste Courrèges3, Nouria Mesli3, Juliane Berchoud10, Maud Toulmonde3, Antoine Italiano3, Axel Le Cesne2, Nicolas Penel8, Francoise Ducimetiere2, Francois Gouin2, Jean-Michel Coindre3, Jean-Yves Blay2,27,28.   

Abstract

BACKGROUND: Since 2010, nationwide networks of reference centers for sarcomas (RREPS/NETSARC/RESOS) collected and prospectively reviewed all cases of sarcomas and connective tumors of intermediate malignancy (TIM) in France.
METHODS: The nationwide incidence of sarcoma or TIM (2013-2016) was measured using the 2013 WHO classification and confirmed by a second independent review by expert pathologists. Simple clinical characteristics, yearly variations and correlation of incidence with published clinical trials are presented and analyzed.
RESULTS: Over 150 different histological subtypes are reported from the 25172 patients with sarcomas (n = 18712, 74,3%) or TIM (n = 6460, 25.7%), with n = 5838, n = 6153, n = 6654, and n = 6527 yearly cases from 2013 to 2016. Over these 4 years, the yearly incidence of sarcomas and TIM was therefore 70.7 and 24.4 respectively, with a combined incidence of 95.1/106/year, higher than previously reported. GIST, liposarcoma, leiomyosarcomas, undifferentiated sarcomas represented 13%, 13%, 11% and 11% of tumors. Only GIST, as a single entity had a yearly incidence above 10/106/year. There were respectively 30, 64 and 66 different histological subtypes of sarcomas or TIM with an incidence ranging from 10 to 1/106, 1-0.1/106, or < 0.1/106/year respectively. The 2 latter incidence groups represented 21% of the patients with 130 histotypes. Published phase III and phase II clinical trials (p<10-6) are significantly higher with sarcomas subtypes with an incidence above 1/106 per.
CONCLUSIONS: This nationwide registry of sarcoma patients, with exhaustive histology review by sarcoma experts, shows that the incidence of sarcoma and TIM is higher than reported, and that tumors with a very low incidence (1<106/year) are less likely to be included in clinical trials.

Entities:  

Mesh:

Year:  2021        PMID: 33630918      PMCID: PMC7906477          DOI: 10.1371/journal.pone.0246958

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  28 in total

1.  Rare cancers are not so rare: the rare cancer burden in Europe.

Authors:  Gemma Gatta; Jan Maarten van der Zwan; Paolo G Casali; Sabine Siesling; Angelo Paolo Dei Tos; Ian Kunkler; Renée Otter; Lisa Licitra; Sandra Mallone; Andrea Tavilla; Annalisa Trama; Riccardo Capocaccia
Journal:  Eur J Cancer       Date:  2011-10-25       Impact factor: 9.162

2.  Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).

Authors:  Roberta Sanfilippo; Robin L Jones; Jean-Yves Blay; Axel Le Cesne; Salvatore Provenzano; Georgios Antoniou; Olivier Mir; Giovanni Fucà; Elena Fumagalli; Rossella Bertulli; Silvia Stacchiotti; Mehdi Brahmi; Federica Grosso; Armelle Dufresne; Nadia Hindi; Marta Sbaraglia; Alessandro Gronchi; Paola Collini; Angelo P Dei Tos; Paolo G Casali
Journal:  Clin Cancer Res       Date:  2019-06-19       Impact factor: 12.531

3.  Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Margaret von Mehren; R Lor Randall; Robert S Benjamin; Sarah Boles; Marilyn M Bui; Ernest U Conrad; Kristen N Ganjoo; Suzanne George; Ricardo J Gonzalez; Martin J Heslin; John M Kane; Henry Koon; Joel Mayerson; Martin McCarter; Sean V McGarry; Christian Meyer; Richard J O'Donnell; Alberto S Pappo; I Benjamin Paz; Ivy A Petersen; John D Pfeifer; Richard F Riedel; Scott Schuetze; Karen D Schupak; Herbert S Schwartz; William D Tap; Jeffrey D Wayne; Mary Anne Bergman; Jillian Scavone
Journal:  J Natl Compr Canc Netw       Date:  2016-06       Impact factor: 11.908

4.  Incidence, mortality, and survival trends of soft tissue and bone sarcoma in Switzerland between 1996 and 2015.

Authors:  Attila Kollár; Christian Rothermundt; Frank Klenke; Beata Bode; Daniel Baumhoer; Volker Arndt; Anita Feller
Journal:  Cancer Epidemiol       Date:  2019-09-11       Impact factor: 2.984

5.  A population-based study of soft tissue sarcoma incidence and survival in Australia: An analysis of 26,970 cases.

Authors:  Taryn Bessen; Gillian E Caughey; Sepehr Shakib; J Alexa Potter; Jessica Reid; Gelareh Farshid; David Roder; Susan J Neuhaus
Journal:  Cancer Epidemiol       Date:  2019-09-11       Impact factor: 2.984

6.  Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions.

Authors:  Lionel Perrier; Alessandra Buja; Giuseppe Mastrangelo; Antonella Vecchiato; Paolo Sandonà; Françoise Ducimetière; Jean-Yves Blay; François Noël Gilly; Carole Siani; Pierre Biron; Dominique Ranchère-Vince; Anne-Valérie Decouvelaere; Philippe Thiesse; Christophe Bergeron; Angelo Paolo Dei Tos; Jean-Michel Coindre; Carlo Riccardo Rossi; Isabelle Ray-Coquard
Journal:  BMC Health Serv Res       Date:  2012-03-28       Impact factor: 2.655

7.  Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.

Authors:  Anna Maria Frezza; Tarek Assi; Salvatore Lo Vullo; Eytan Ben-Ami; Armelle Dufresne; Kan Yonemori; Emi Noguchi; Brittany Siontis; Richard Ferraro; Pawel Teterycz; Florence Duffaud; Vinod Ravi; Bruno Vincenzi; Hans Gelderblom; Maria A Pantaleo; Giacomo G Baldi; Ingrid Desar; Alexander Fedenko; Robert G Maki; Robin L Jones; Robert S Benjamin; Jean Yves Blay; Akira Kawai; Mrinal Gounder; Alessandro Gronchi; Axel Le Cesne; Olivier Mir; Anna M Czarnecka; Scott Schuetze; Andrew J Wagner; Julien Adam; Marta Barisella; Marta Sbaraglia; Jason L Hornick; Alexandra Meurgey; Luigi Mariani; Paolo G Casali; Katherine Thornton; Silvia Stacchiotti
Journal:  Cancer       Date:  2019-09-19       Impact factor: 6.921

8.  The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group.

Authors:  Lionel Perrier; Pauline Rascle; Magali Morelle; Maud Toulmonde; Dominique Ranchere Vince; Axel Le Cesne; Philippe Terrier; Agnès Neuville; Pierre Meeus; Fadila Farsi; Françoise Ducimetière; Jean-Yves Blay; Isabelle Ray Coquard; Jean-Michel Coindre
Journal:  PLoS One       Date:  2018-04-05       Impact factor: 3.240

9.  The Scandinavian Sarcoma Group Central Register: 6,000 patients after 25 years of monitoring of referral and treatment of extremity and trunk wall soft-tissue sarcoma.

Authors:  Clement Trovik; Henrik C F Bauer; Emelie Styring; Kirsten Sundby Hall; Fredrik Vult Von Steyern; Sigvard Eriksson; Ingela Johansson; Mika Sampo; Minna Laitinen; Anders Kalén; Halldór Jónsson; Nina Jebsen; Mikael Eriksson; Erkki Tukiainen; Najme Wall; Olga Zaikova; Helgi Sigurðsson; Tuula Lehtinen; Bodil Bjerkehagen; Mikael Skorpil; Geir Egil Eide; Elisabeth Johansson; Thor A Alvegard
Journal:  Acta Orthop       Date:  2017-03-07       Impact factor: 3.717

10.  Improved survival using specialized multidisciplinary board in sarcoma patients.

Authors:  J-Y Blay; P Soibinet; N Penel; E Bompas; F Duffaud; E Stoeckle; O Mir; J Adam; C Chevreau; S Bonvalot; M Rios; P Kerbrat; D Cupissol; P Anract; F Gouin; J-E Kurtz; C Lebbe; N Isambert; F Bertucci; M Toumonde; A Thyss; S Piperno-Neumann; P Dubray-Longeras; P Meeus; F Ducimetière; A Giraud; J-M Coindre; I Ray-Coquard; A Italiano; A Le Cesne
Journal:  Ann Oncol       Date:  2017-11-01       Impact factor: 32.976

View more
  18 in total

1.  Soft tissue solitary fibrous tumors of the musculoskeletal system: spectrum of MRI appearances and characteristic imaging features.

Authors:  Vimarsha G Swami; Elizabeth G Demicco; Ali Naraghi; Lawrence M White
Journal:  Skeletal Radiol       Date:  2021-08-25       Impact factor: 2.199

Review 2.  Small round cell sarcomas.

Authors:  Florencia Cidre-Aranaz; Sarah Watson; James F Amatruda; Takuro Nakamura; Olivier Delattre; Enrique de Alava; Uta Dirksen; Thomas G P Grünewald
Journal:  Nat Rev Dis Primers       Date:  2022-10-06       Impact factor: 65.038

Review 3.  Regorafenib for the Treatment of Sarcoma.

Authors:  Jean-Yves Blay; Florence Duffaud; Suzanne George; Robert G Maki; Nicolas Penel
Journal:  Curr Treat Options Oncol       Date:  2022-09-30

4.  Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour.

Authors:  Tatiana Georgiesh; Ninna Aggerholm-Pedersen; Patrick Schöffski; Yifan Zhang; Andrea Napolitano; Judith V M G Bovée; Åse Hjelle; Gordon Tang; Mateusz Spalek; Margherita Nannini; David Swanson; Thomas Baad-Hansen; Raf Sciot; Asle C Hesla; Paul Huang; Desiree Dorleijn; Hans Kristian Haugland; Maribel Lacambra; Jacek Skoczylas; Maria A Pantaleo; Rick L Haas; Leonardo A Meza-Zepeda; Florian Haller; Anna M Czarnecka; Herbert Loong; Nina L Jebsen; Michiel van de Sande; Robin L Jones; Felix Haglund; Iris Timmermans; Akmal Safwat; Bodil Bjerkehagen; Kjetil Boye
Journal:  Br J Cancer       Date:  2022-08-27       Impact factor: 9.075

5.  Peritoneal Carcinomatosis as an Initial Presentation of Gastrointestinal Stromal Tumor: A Case Report and Review of the Literature.

Authors:  Gonca Ozcan; Garima Gautam; Teresa Da Cunha; Erica C Becker; Nikola Perosevic
Journal:  Cureus       Date:  2022-06-29

6.  No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks' Outcome?

Authors:  Yohan Fayet; Christine Chevreau; Gauthier Decanter; Cécile Dalban; Pierre Meeus; Sébastien Carrère; Leila Haddag-Miliani; François Le Loarer; Sylvain Causeret; Daniel Orbach; Michelle Kind; Louis-Romée Le Nail; Gwenaël Ferron; Hélène Labrosse; Loïc Chaigneau; François Bertucci; Jean-Christophe Ruzic; Valérie Le Brun Ly; Fadila Farsi; Emmanuelle Bompas; Sabine Noal; Aurore Vozy; Agnes Ducoulombier; Clément Bonnet; Sylvie Chabaud; Françoise Ducimetière; Camille Tlemsani; Mickaël Ropars; Olivier Collard; Paul Michelin; Justine Gantzer; Pascale Dubray-Longeras; Maria Rios; Pauline Soibinet; Axel Le Cesne; Florence Duffaud; Marie Karanian; François Gouin; Raphaël Tétreau; Charles Honoré; Jean-Michel Coindre; Isabelle Ray-Coquard; Sylvie Bonvalot; Jean-Yves Blay
Journal:  Cancers (Basel)       Date:  2022-05-25       Impact factor: 6.575

7.  Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities.

Authors:  Silvia Stacchiotti; Anna Maria Frezza; Jean-Yves Blay; Elizabeth H Baldini; Sylvie Bonvalot; Judith V M G Bovée; Dario Callegaro; Paolo G Casali; RuRu Chun-Ju Chiang; George D Demetri; Elisabeth G Demicco; Jayesh Desai; Mikael Eriksson; Hans Gelderblom; Suzanne George; Mrinal M Gounder; Alessandro Gronchi; Abha Gupta; Rick L Haas; Andrea Hayes-Jardon; Peter Hohenberger; Kevin B Jones; Robin L Jones; Bernd Kasper; Akira Kawai; David G Kirsch; Eugene S Kleinerman; Axel Le Cesne; Jiwon Lim; María Dolores Chirlaque López; Roberta Maestro; Rafael Marcos-Gragera; Javier Martin Broto; Tomohiro Matsuda; Olivier Mir; Shreyaskumar R Patel; Chandrajit P Raut; Albiruni R A Razak; Damon R Reed; Piotr Rutkowski; Roberta G Sanfilippo; Marta Sbaraglia; Inga-Marie Schaefer; Dirk C Strauss; Kirsten Sundby Hall; William D Tap; David M Thomas; Winette T A van der Graaf; Winan J van Houdt; Otto Visser; Margaret von Mehren; Andrew J Wagner; Breelyn A Wilky; Young-Joo Won; Christopher D M Fletcher; Angelo P Dei Tos; Annalisa Trama
Journal:  Cancer       Date:  2021-04-28       Impact factor: 6.860

8.  Localized Angiosarcoma, Not One Disease: A Retrospective Single-Center Study on Prognosis Depending on the Primary Site and Etiology.

Authors:  Inna Schott; Sven-Thorsten Liffers; Farhad Farzaliyev; Johanna Falkenhorst; Hans-Ulrich Steinau; Jürgen-Walter Treckmann; Lars Erik Podleska; Christoph Pöttgen; Hans-Ulrich Schildhaus; Marit Ahrens; Uta Dirksen; Fatma-Zehra Murat; Jens T Siveke; Sebastian Bauer; Rainer Hamacher
Journal:  Sarcoma       Date:  2021-09-10

9.  European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN.

Authors:  J-Y Blay; P Casali; C Bouvier; C Dehais; I Galloway; J Gietema; J Halámková; N Hindi; A Idbaih; E Kinloch; H-J Klümpen; T Kolarova; K Kopeckova; J Lovey; M Magalhaes; K Oselin; S Piperno-Neumann; A Ravnsbaek; M Rogasik; A Safwat; S Scheipl; M Seckl; J Taylor; M Temnyk; A Trama; M Urbonas; M Wartenberg; A Weinman
Journal:  ESMO Open       Date:  2021-06-14

10.  Digital Pathology Transformation in a Supraregional Germ Cell Tumour Network.

Authors:  Richard Colling; Andrew Protheroe; Mark Sullivan; Ruth Macpherson; Mark Tuthill; Jacqueline Redgwell; Zoe Traill; Angus Molyneux; Elizabeth Johnson; Niveen Abdullah; Andrea Taibi; Nikki Mercer; Harry R Haynes; Anthony Sackville; Judith Craft; Joao Reis; Gabrielle Rees; Maria Soares; Ian S D Roberts; Darrin Siiankoski; Helen Hemsworth; Derek Roskell; Sharon Roberts-Gant; Kieron White; Jens Rittscher; Jim Davies; Lisa Browning; Clare Verrill
Journal:  Diagnostics (Basel)       Date:  2021-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.